Early June.
Jinling Medical University.
Professor's office.
Zhou Jin, as usual, was browsing the latest issue of Cell journal.
As one of the world's top academic journals.
Every paper published represents the cutting edge of the medical field today.
He admired several papers silently.
These papers are all of the highest quality.
Suddenly...
A paper titled "A New Generation of Immune Checkpoint Inhibitors is Emerging" caught his attention.
The author of the paper was Zhao Yan, a student from Gusu University in Xia Country.
In the paper, Zhao Yan and his team found.
NKG2A antibodies, as a new type of immune checkpoint inhibitor, could potentially enhance the anti-tumor ability of T cells and natural killer cells (NK cells), and when combined with existing cancer immunotherapy, could better treat cancer patients.
The key to this study lies in a receptor molecule called NKG2A.
Zhao Yan's team discovered that blocking this receptor could enhance the immune activity of NK cells and T cells in mice, thereby improving the anti-tumor immune response.
To this end, they developed an NKG2A antibody called Monalizumab.
It is a humanized monoclonal antibody.
In the experiment, Zhao Yan's team divided the mice into four groups. The first group of mice received only Monalizumab monoclonal antibody, the second group received only PD-L1 monoclonal antibody, the third group received a combination of Monalizumab monoclonal antibody and PD-L1 monoclonal antibody, and the fourth group served as a control group.
These mice were previously inoculated with B-cell lymphoma cells through subcutaneous injection.
They found that compared to the control group, giving only PD-L1 monoclonal antibody could allow up to 40% of the mice to survive, giving Monalizumab monoclonal antibody alone did not have a significant anti-cancer effect, but giving a combination of the two monoclonal antibodies could allow up to 75% of the mice to survive, which revealed that NKG2A monoclonal antibody combination therapy has great anti-cancer potential.
In human clinical trials.
Zhao Yan's team divided 30 patients with squamous cell carcinoma of the head and neck into multiple groups and received different doses of Monalizumab monoclonal antibody.
Clinical trial results show that.
Monalizumab monoclonal antibody is very safe, and the most common adverse reactions are fatigue, fever and headache.
Therefore, it is clear that.
As a new type of immune checkpoint inhibitor.
NKG2A antibodies can promote anti-tumor immune responses by enhancing the activity of T cells and NK cells, and can be used as a supplement to first-generation cancer immunotherapy.
After reading the entire paper.
Zhou Jin was full of admiration.
Zhao Yan's team's paper is of the highest standard.
Obviously, Cell journal also took this into account and published this valuable paper.
...
Next.
Zhou Jin continued to browse the Cell journal.
As he looked.
He was stunned.
He saw that many of the authors of this week's journal were from Gusu University.
Cell: Conduction Pathway from Nasal Mucosal Sensory Nerve Fibers to Brainstem Respiratory Nucleus. – First author: Liu Qi (Gusu University).
Cell: A New Map Provides New Insights into How Genes Function During Early Embryonic Development – First author: Tong Rui (Gusu University).
Cell: New Research Reveals the Mechanism by Which ARID1A Gene Mutations Sensitize Cancer Patients to Immunotherapy – First author: Huang Teng (Gusu University).
Cell: Perturb-seq Technology is Used to Large-Scale Explore Brain Cell Types Associated with Key Developmental Genes – First author: Guo Fei (Gusu University).
Cell: As We Age, Hematopoietic Stem Cells Produce Highly Reactive Secondary Platelet Skirt Bodies, Leading to Increased Coagulation – First author: Fang Lingling (Gusu University).
...
In this issue.
At least 15 medical papers from Gusu University students.
To this, Zhou Jin was speechless.
As a top academic journal with an impact factor of 33.116.
Every paper published is a cutting-edge scientific research achievement in the academic world.
But now...
Gusu University students seem to be publishing papers as easily as eating and drinking, with 15 papers published lightly.
Are they so good?
...
With strong curiosity, Zhou Jin quickly flipped through the latest issues of Nature and Science journals.
Science: New Research Discovers that NLRC5 Triggers Widespread Cell Apoptosis Mechanism – First author: Shen Chao (Gusu University).
Science: Primitive Endodermal Stem Cells Have Amazing Self-Renewal Potential and Can Reconstruct Embryos – First author: Li Mo (Gusu University).
Science: mRNA Level Changes in Germ Cells and Somatic Cells Affect the Lifespan of Different Host Individuals – First author: Yao Le (Gusu University).
Science: New Research Reveals How Perivascular Neurons Build a Three-Dimensional Vascular Structure to Maintain Retinal Health – First author: Zhang Hao (Gusu University).
Science: Unexpected Surprises with Flatulence? Gut Bacteria Convert Corticosteroids to Progesterone Derivatives in the Presence of Hydrogen, Affecting Women's Health and Postpartum Mood – First author: Xia Qian (Gusu University).
...
Nature: New Research Discovers a Direct Communication Pathway Between the Lungs and the Brain – First author: Chen Yu (Gusu University).
Nature: Revealing the Key Role of Lymphatic Vessels in Bone and Blood Cell Regeneration – First author: Chen Yu (Gusu University).
Nature: Blocking the Reactivation and Spread of Endogenous Retroviruses Can Alleviate Organismal Aging – First author: Chen Yu (Gusu University).
Nature: Neonatal Neutropenia May Result from Suppression of Fetal Hematopoietic Stem Cells – First author: Chen Yu (Gusu University).
Nature: Immunotherapy also has a Golden Window! Revealing the Importance of the Circadian Rhythm of the Immune System for Tumor Growth – First author: Chen Yu (Gusu University).
...
Nature: Fetal Cells Can be Traced Back to the First Day of Human Embryonic Development – First author: Wang Xu (Gusu University).
Nature: Neutrophil Response Associated with Tumor Control in Immunotherapy – First author: Xu Shi (Gusu University).
Nature: Single-Cell Sequencing Applied to Construct a Spatiotemporal Dynamic Map of Macrophage Development – First author: Dong Jun (Gusu University).
...
After reading a series of papers.
Zhou Jin was already amazed.
He counted roughly.
In this week's Science journal, 12 papers were from students at Gusu University.
In this week's Nature journal, 20 papers were from Gusu University, of which 10 were from Associate Professor Chen Yu of Gusu University, and the remaining 10 were from Gusu University students.
This is simply too exaggerated!
...
At the same time.
Domestic experts and scholars are all discussing Gusu University.
Not counting Chen Yu's 10 Nature papers.
This week, Gusu University students published 37 CNS papers, which is incredibly strong!
To this, scholars are both shocked and comforted.
The shock is that the academic level of Gusu University students has made a sudden leap forward, which is astonishing.
The comfort is that the higher the medical level of Gusu University students, the higher the overall academic level of Xia Country will be.
...
Looking back at the domestic higher education circle.
Students from all schools are dumbfounded.
What's going on?
This month, Gusu University students have 37 medical papers published in CNS journals?
In their usual impression.
Students focus on their GPA in their freshman year, competitions in their sophomore year, and research papers in their junior year.
During undergraduate studies, publishing articles in CNS journals is undoubtedly a true academic god.
During master's studies, publishing articles in CNS journals means that the student is the mentor's favorite and the school's face.
During doctoral studies, publishing articles in CNS journals makes it very easy to go abroad for further studies at famous universities.
But these Gusu University students are all medical undergraduates!
How can they be so awesome?
You guys are all cheating, aren't you?!